STU2 Publication Request - Specialty Medication Enrollment

1. Published Name of the Standard for which request is being made (if previously published) Specialty Medication Enrollment 2. Standards Material/Document STU 3. Date of Request Mar 06, 2023 4. Use Period Two years 5. Reason for extension, timeline, and actions 6. Original Publication Date 7. End date of the current STU period Apr 26, 2023 8. Length of the requested extension 9. Review Process 10. HL7 Work Group making this request and date Pharmacy Work Group 10a. Requesting WG Date Mar 06, 2023 11. URL of approval minutes https://confluence.hl7.org/pages/viewpage.action?pageId=161054823#id-20230306Agenda/MeetingNotes-SpecialtyMedicationEnrolmentIG 12. HL7 Product Management Group FHIR Management Group 12a. Management Group Date of Approval Mar 29, 2023 13. URL of approval minutes https://confluence.hl7.org/pages/viewpage.action?pageId=161061400 14. Is the artifact ready for final publication? Yes 15. If not ready, please describe remaining steps. 16. Tool name used to produce the machine processable artifacts in the IG FHIR IG Publisher 17. The name of the “IG artifact” within the context of the above mentioned tool. Specialty Medication Enrollment (specialty-rx.xml) 18. Balloted Name of the standard for which request is being made Specialty Medication Enrollment 19. Requested name for published standard. See Naming Examples Specialty Medication Enrollment 19a. Specification Feedback Name (For Search in Jira) 20. If CMET, list IDs balloted 21. Project Insight Number 1573 22. Document Realm U.S. Realm Specific 23. Ballot cycle in which the document was successfully balloted 2022-SEP 25. Affirmative 77 26. Negative 3 27. Abstentions 33 28. Not Returned 33 29. Total in ballot pool 146 30. Date on which final document/standards material was supplied to HQ 31. URL of publication material/ SVN repository https://github.com/HL7/fhir-specialty-rx 32. Publishing Facilitator Frank McKinney 33. Special Publication Instructions 34. URL of ballot reconciliation document https://jira.hl7.org/secure/attachment/23621/reconciliation.xls 35. Has the Work Group posted its consideration of all comments received in its reconciliation document on the ballot desktop? Yes 36. Substantive Changes Since Last Ballot? Yes 37. Product Brief Reviewed By Pharmacy Work Group 38. Date Product Brief Reviewed Mar 06, 2023 39. Has the Product Brief changed? 40. Family FHIR 41. Section Implementation Guides 42. Topic Medical Records Patient Care Pharmacy 43. Please Describe the Topic 44. Product Type Implementation Guide 45. Parent standard FHIR 46. Parent Standard Status Active 47. Update/replace standard Replace published STU1 of this Implementation Guide 48. Common name/search keyword Specialty Medication Enrollment 49. Description This FHIR implementation Guide describes the exchange of patient demographic, clinical, consent and coverage data to support fulfillment of specialty medication prescriptions by pharmacies, and enrollment of patients into related support programs offered by parties such as Hub vendors and pharmaceutical manufacturers. 50. Stakeholders Other (specify in text box below) 51. Vendors EHR, PHR, Health Care IT, Other (please specify) 52. Providers Healthcare Institutions (hospitals, long term care, home care, mental health) Other (specify in text box below) 53. Benefits Enables pharmacies and related parties to obtain the demographic, clinical, coverage and coverage information needed to dispense specialty medications in the US and enroll patients in related support programs. 54. Implementations/Case Studies Pharmacy systems / specialty HUB systems / EHRs. The supported use cases enable (a) the prescriber's EHR to proactively exchange patient information with the pharmacy or HUB, (b) the pharmacy or HUB to systematically query patient information, (c) the pharmacy or HUB to obtain information that requires human interaction by the prescriber or their staff, and (d) the pharmacy or HUB to obtain consent information needed during dispensing of the medication. 55. Development Background This Implementation Guide was developed in cooperation with the National Council for Prescription Drug Programs (NCPDP).